Pre-clinical models of Intestinal Toxicity

This webinar is aimed at informing end-users involved in pre-clinical drug screening (discovery and development) of the models and techniques available to elucidate the causes and consequences of gastrointestinal (GI) toxicities and pathologies. This information will ultimately help users design dose schedules and formulations that can minimise such effects, or quickly identify test articles that have a high likelihood of toxicity in vivo or in the clinic. Dr. Booth has been a key opinion leader is this field for 25 years, working with many different biotechnology and pharmaceutical companies to design and perform studies that address their pertinent questions. This webinar will review some of the models in use and discuss current practice when running pre-clinical studies for sponsors at Epistem. Specifically, there will be an overview of:

• The implications of the timings of observed toxicity
• The consequences of interrupted cell production or cell death in various tissue populations
• The techniques available to measure perturbed barrier function
• Predictive in vitro screening techniques to identify articles likely to cause in vivo toxicity

Historical data will be presented to illustrate the techniques and responses to known therapeutics, along with typical study designs and readouts.

The aim of this webinar is to enable the end-user to select the best model and study design to predict or assess GI toxicity.

Speaker

Cath Booth, PhD, Co-founder and Managing Director, Contract Research Services, Epistem

Dr. Booth received her PhD in 1991 from the University of Cambridge, England, after completing her studies at the multi-Nobel prize winning MRC Laboratory of Molecular Biology. Subsequently, she spent 10 years within academic research, working in Professor Chris Potten’s laboratory at The Paterson Institute for Cancer Research, Manchester, England. This work focussed on epithelial biology, particularly the control of cell turnover in the gastrointestinal epithelium, and the role of the stem cells and apoptosis in controlling epithelial damage and repair following radio- or chemotherapy. She co-founded Epistem with Professor Potten in 2000, in order to harness this in-depth knowledge to assist biotechnology and Pharmaceutical companies with their pre-clinical discovery and development portfolios. Dr. Booth has published over 60 papers, spoken at many international conferences and performed a key advisory role for pertinent U.S. Government bodies, the U.S. FDA, and for numerous companies on this subject matter. Most recently, Dr. Booth has been involved in developing validated models of gastrointestinal radiation damage in order to evaluate novel therapies

Message Presenter